DRUG AND CARDIAC RESYNCHRONIZATION THERAPY IN THE TREATMENT OF CHRONIC HEART FAILURE (LITERATURE REVIEW)

The article deals with the role of pharmacological agents and implantable devices in the treatment of chronic heart failure (CHF) with different ejection fraction: preserved ejection fraction, mildly reduced ejection fraction and reduced ejection fraction (HFpEF, CHFmrEFV, CHFrFV). The authors emphasise that despite the widespread introduction of angiotensin receptor and neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MCRAs) and sodium-glucose cotransporter inhibitors (SGLT2) into practice, there is still a high residual risk of unfavorable outcomes in patients with both HFpEF and CHFmrEFV, CHFrFV. Therefore, therapies using implantable cardioverter-defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) are evolving. The review is based on data from PubMed and Google Scholar databases for the last 5 years.